Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Lucitanib dihydrochloride (Synonyms: E-3810 dihydrochloride, E3810 dihydrochloride, CO-3810 dihydrochloride, ...)

Name: Lucitanib dihydrochloride
Brand: TargetMol
SKU: T89507
Rating: 4.5 (1 reviews)

Catalog No. T89507 Copy Product Info

🥰Excellent

Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFRalpha/β, useful in metastatic breast cancer research.

Lucitanib dihydrochloride

Copy Product Info

🥰Excellent

Catalog No. T89507

Synonyms E-3810 dihydrochloride, E3810 dihydrochloride, CO-3810 dihydrochloride, CO3810 dihydrochloride, AL3810 dihydrochloride, AL 3810 dihydrochloride

Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFRalpha/β, useful in metastatic breast cancer research.

Cas No. 2108875-91-6

Pack Size	Price	USA Stock	Global Stock	Quantity
10 mg	Inquiry	10-14 weeks	10-14 weeks
50 mg	Inquiry	10-14 weeks	10-14 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:Yellow

Resource Download

COA

Product Introduction

Bioactivity

Description	Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFRalpha/β, useful in metastatic breast cancer research.
Targets&IC50	FGFR1:17.5 nM, VEGFR1:7 nM, FGFR2:82.5 nM, VEGFR3:10 nM, VEGFR2:25 nM
In vitro	Lucitanib dihydrochloride (E-3810 dihydrochloride) has potent inhibitory effects on VEGFR and FGFR autophosphorylation and can effectively inhibit VEGF- and bFGF-induced HUVEC proliferation with IC50 values of 40 and 50 nM, respectively. It can also inhibit CSF-1R with an IC50 value of 5 nM. [1]
In vivo	Lucitanib dihydrochloride (E-3810 dihydrochloride) (20 mg/kg, oral, 7 days) treated mice, Lucitanib completely inhibited the bFGF-induced angiogenic response. Methods: Lucitanib dihydrochloride (15 mg/kg, oral, 30 days) was treated in mice bearing the MDA-MB-231 advanced breast cancer model, and tumor size was evaluated in vivo. Results: Lucitanib dihydrochloride effectively stabilized tumor growth. [3]
Synonyms	E-3810 dihydrochloride, E3810 dihydrochloride, CO-3810 dihydrochloride, CO3810 dihydrochloride, AL3810 dihydrochloride, AL 3810 dihydrochloride

Chemical Properties

Molecular Weight	516.42
Formula	C₂₆H₂₇Cl₂N₃O₄
Cas No.	2108875-91-6
Smiles	O=C(C1=CC=CC2=CC(OC3=C4C=C(OC)C(OCC5(CC5)N)=CC4=NC=C3)=CC=C21)NC.Cl.Cl

Storage & Solubility Information

Storage

store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 16 mg/mL (30.98 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9364 mL	9.6820 mL	19.3641 mL	96.8204 mL
5 mM	0.3873 mL	1.9364 mL	3.8728 mL	19.3641 mL
10 mM	0.1936 mL	0.9682 mL	1.9364 mL	9.6820 mL
20 mM	0.0968 mL	0.4841 mL	0.9682 mL	4.8410 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc